New molecular insights into cancer stem cells have highlighted their potential as therapeutic targets. 

In a recent study, researchers have revealed how transcription factors CDX1 and CDX2 suppress cancer cell stemness by blocking β-catenin’s ability to activate key genes like LGR5.  

Their findings showed that CDX1/2 prevent the formation of key transcriptional complexes involving DSIF and PAF1, identifying these as critical regulators and potential therapeutic targets in colon cancer. 

A study led by Professor Koji Aoki from the Department of Pharmacology, Faculty of Medicine at the University of Fukui, Japan, and published in journal Cell Death & Disease, found that the complete loss of CDX1, or the combined loss of CDX1 and CDX2, increased the aggressiveness of tumours in mice.  

These tumours showed higher expression of LGR5 and CD44—two genes strongly associated with cancer stemness—and were more invasive. 

Central players in colon cancer

When CDX1 or CDX2 was artificially reintroduced into cancer cells, the expression of these stemness-related genes sharply decreased, suggesting a suppressive role of CDX1/2. The team observed that CDX1/2 bind to a specific region downstream of the starting point of the LGR5 gene, a region also targeted by β-catenin.  

Surprisingly, even though CDX1/2 promoted an open chromatin structure usually associated with active gene expression, they still significantly reduced the presence of key transcriptional components around LGR5’s starting site. 

The researchers also found that CDX1/2 directly interfere with β-catenin’s ability to assemble the active form of Pol II complexes, which include DSIF and PAF1.  

CDX1/2 prevented the direct interaction between β-catenin and these transcription factors due to their functional homeodomains. 

This positions DSIF and PAF1 complexes as central players in the pathophysiology of colon cancer, marking them as potential therapeutic targets of future drugs. 

Professor Aoki explained: “Our results suggest that DSIF and PAF1 complexes act as transcriptional platforms that integrate and funnel both tumour-suppressive and oncogenic signals into the expression of genes that control colon cancer stemness. Further investigation of stemness-related transcriptional mechanisms will aid in the development of drugs to effectively treat colon cancer.”

Diana Turner, Senior Digital Content Editor, DDW